BMI changes in pediatric type 1 narcolepsy under sodium oxybate treatment
| Autor: | Fabio Pizza, Andrea Pession, Luca Vignatelli, Virginia Ponziani, Giuseppe Plazzi, Corrado Zenesini |
|---|---|
| Přispěvatelé: | Ponziani V., Pizza F., Zenesini C., Vignatelli L., Pession A., Plazzi G. |
| Rok vydání: | 2021 |
| Předmět: |
obesity
medicine.medical_specialty Cataplexy childhood type 1 narcolepsy Overweight Body Mass Index Childhood Type 1 narcolepsy sodium oxybate Retrospective Studie Weight loss Physiology (medical) Internal medicine medicine Humans Child Narcolepsy Retrospective Studies business.industry Retrospective cohort study medicine.disease Obesity Neurology (clinical) medicine.symptom Sodium Oxybate business Body mass index Weight gain Human |
| Zdroj: | Sleep. 44 |
| ISSN: | 1550-9109 0161-8105 |
| DOI: | 10.1093/sleep/zsaa295 |
| Popis: | Pediatric type 1 narcolepsy (NT1) is often associated with overweight and obesity. Sodium oxybate (SO), approved for the treatment of narcolepsy with cataplexy from the age of 7 years old in the United States, has been associated with weight loss, although longitudinal pediatric studies are lacking. We report a retrospective cohort of 129 consecutive patients with a 4-year follow-up, to analyze the impact of different pharmacological treatments on body mass index (BMI) z-score. At baseline, the prevalence of obesity and overweight was 26.4% (34/129) and 29.5% (38/129), respectively. Patients were divided into three groups: children treated with SO alone (group 1), with SO-combined therapy (group 2), and without SO (group 3). At the end of the first year of follow-up, group 1 and group 2 showed a significant BMI z-score reduction compared to baseline: from 1.2 ± 1.1 to 0.4 ± 1.4 for group 1 (p < 0.001), and from 1.4 ± 1.1 to 1 ± 1.3 for group 2 (p = 0.002), independently from baseline clinical features. In the second year, only group 2 experienced a further and significant BMI z-score decrease (from 1.0 ± 1.2 to 0.6 ± 1.2, p = 0.037). No further significant BMI z-score changes were observed in SO-treated patients in the following years. Instead, children treated without SO developed a significant weight increase between the second and third year of therapy (BMI z-score from 0.3 ± 0.9 to 0.5 ± 0.9). In conclusion, SO treatment in pediatric NT1 is associated with a favorable weight reduction in the first year of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|